Table 4.

All-causality grade 3 or 4 adverse events by ALBI grade (safety population)^a.

	ALBI grade 1		ALBI grade 2
	Cabozantinib (N = 186)	Placebo (N = 102)	Cabozantinib (N = 279)	Placebo (N = 133)
Any grade 3 or 4 adverse event, n (%)	140 (75)	35 (34)	176 (63)	50 (38)
Hypertension	40 (22)	3 (3)	34 (12)	1 (1)
PPE	33 (18)	0	46 (16)	0
Diarrhea	25 (13)	1 (1)	21 (8)	3 (2)
AST increased	15 (8)	4 (4)	40 (14)	11 (8)
Fatigue	14 (8)	2 (2)	35 (13)	8 (6)
Decreased appetite	9 (5)	0	18 (6)	1 (1)
Asthenia	8 (4)	2 (2)	24 (9)	2 (2)
Anemia	5 (3)	1 (1)	14 (5)	11 (8)

ALBI albumin–bilirubin, AST aspartate aminotransferase, PPE palmar-plantar erythrodysesthesia.

^aEvents that occurred at ≥5.0% frequency in either treatment arm in the overall safety population are summarised.